# Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

> **NCT02235662** · PHASE1 · COMPLETED · sponsor: **CONRAD** · enrollment: 86 (actual)

## Conditions studied

- HIV
- Contraception

## Interventions

- **DRUG:** TFV IVR
- **DRUG:** TFV/LNG IVR
- **OTHER:** Placebo IVR

## Key facts

- **NCT ID:** NCT02235662
- **Lead sponsor:** CONRAD
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 86 (ACTUAL)
- **Last updated:** 2016-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02235662

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02235662, "Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02235662. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*